Clinical Trials Logo

Filter by:
NCT ID: NCT05962021 Not yet recruiting - Clinical trials for EGFR Positive Non-small Cell Lung Cancer

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential predictive and prognostic biomarkers, aiming to provide more abundant evidences for the preoperative treatment decision of non-squamous NSCLC patients.

NCT ID: NCT05962619 Not yet recruiting - Clinical trials for Temporomandibular Joint Dysfunction Syndrome

Arthrocentesis Alone Versus Arthrocentesis With Hyaluronic Acid Injection

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Comparison between Arthrocentesis alone arthrocentesis with hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction.

NCT ID: NCT05962983 Not yet recruiting - PreDiabetes Clinical Trials

Small Steps for Big Changes - Recipe for Health

RFH
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate changes in HbA1c levels, diet, weight and waist circumference in Small Steps for Big Changes (SSBC) diabetes prevention program participants two year after program completion compared to before they took part in the program. The main questions it aims to answer are: 1. Are changes in caloric, carbohydrate, and fibre intake associated with HbA1c levels after SSBC program completion in the short (3- and 6- months), medium (9- and 12- months) and long-term (21- and 24- months)? 2. Are changes in caloric, carbohydrate, and fibre intake associated with anthropometrics (weight and waist circumference) after program completion in the short (3- and 6- months), medium (9- and 12- months) and long-term (21- and 24- months)? 3. Are eating motives associated with dietary intake in individuals with prediabetes? 4. Does participation in SSBC result in changes to eating motives over time? It is hypothesized that: 1. Dietary changes will be associated with HbA1c levels at 3-, 6-,12- and 24- months post-intervention. 2. Dietary changes will be associated with weight and waist circumference at 3-, 6-, and 12-months post-intervention. 3. Participants' eating motives are associated with their dietary intake. 4. Eating motives will change after partaking in SSBC and at 3-, 6-, 12- months post intervention. A total number of 250 individuals with prediabetes will be recruited to take part in a 6-week diet and exercise changes program (SSBC). The program will be administered and facilitated by the community facility trainers at YMCA locations. Participants will be asked to visit Diabetes Prevention Research Group (DPRG) Lab in the University of British Columbia Okanagan Campus for Hba1c (primary outcome), anthropometric measurements and dietary assessment.

NCT ID: NCT05964426 Not yet recruiting - Clinical trials for Unspecified Fetal and Neonatal Jaundice

Health Literacy of Parents Regarding Neonatal Jaundice

Start date: August 1, 2023
Phase:
Study type: Observational

This study will be conducted as a relational descriptive study to determine the health literacy level of parents with infants between 0-28 days of age regarding neonatal jaundice. The secondary aim of the study is to examine whether the health literacy levels of the parents differ with parent and infant descriptive characteristics and their knowledge about neonatal jaundice. In this study, answers to the following questions were sought. 1. What is the level of knowledge about neonatal jaundice among parents with infants between 0-28 days? 2. What is the level of health literacy of parents with infants between 0-28 days of age and is there a relationship between parent, infant identifying characteristics and knowledge about neonatal jaundice?

NCT ID: NCT05964634 Not yet recruiting - Myopia Clinical Trials

Effect of Peripapillary Atrophy to Diagnose Glaucoma in High Myopia

Start date: August 1, 2023
Phase:
Study type: Observational

This study intends to analyze the characteristics between peripapillary retinal nerve fiber layer thickness and peripapillary area in high myopia with or without glaucoma

NCT ID: NCT05964751 Not yet recruiting - Lupus Nephritis Clinical Trials

the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients

Start date: August 1, 2023
Phase:
Study type: Observational

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that involve s many different organs and display a variable clinical course. The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the reproductive years. In adults, the female to male ratio is 10-15:1. Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. Constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease . Major organ affection in SLE includes Neuropsychiatric involvement (cognitive impairment, depression, psychosis, seizures, stroke, demyelinating syndromes, peripheral neuropathy, etc.) and cardiopulmonary manifestations. Lupus nephritis is the most common of the potentially life-threatening manifestations . Renal involvement is common in SLE and is a significant cause of morbidity and mortality. It is estimated that as many as 90% of patients with SLE will have pathologic evidence of renal involvement on biopsy, but clinically significant nephritis will develop in only 50%. Lupus involvement in the kidney manifests as urinary findings (proteinuria, hematuria, pathologic casts) with or without a rise in serum creatinine. The specific criteria listed for renal involvement are a urine protein > 500 mg/dL or red blood cell casts, Lupus nephritis is often confirmed by kidney biopsy, with the results showing one or more of the classes of lupus nephritis. The metabolic syndrome is a prevalent disorder which is defined by the presence of central obesity, dyslipidemia, hypertension, and disturbed glucose metabolism . It is known that Metabolic syndrome predisposes to cardiovascular disease (CVD) and consequently, to a rise in CVD morbidity and mortality. This syndrome plays a major role in the complex network of systemic pro-inflammatory and prothrombotic states involved in the development of CVD . Compared with patients without Metabolic syndrome, SLE patients from the multinational, multiethnic Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) cohort with the diagnosis of Metabolic syndrome were older, had a higher disease activity, an increased number of recent disease flares, and had accrued more organ damage . Mok et al report that Metabolic syndrome is significantly associated with new organ damage, vascular events, and mortality in patients with SLE .

NCT ID: NCT05965102 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the PD-1 antibody tirelizumab combined with chemotherapy monotherapy in patients with relapsed/metastatic non-small cell lung cancer.

NCT ID: NCT05965141 Not yet recruiting - Ovarian Cancer Clinical Trials

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective phase II, single-center, single-arm clinical study of platinum-sensitive relapsed ovarian cancer. The main objective of this study is to evaluate the efficacy, safety and tolerability of Aribrine combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive relapsed ovarian cancer.

NCT ID: NCT05965154 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, one-arm exploratory second-line study of carrilizumab combined with bevacizumab plus capecitabine in relapsed metastatic squamous cell carcinoma of the head and neck.

NCT ID: NCT05965271 Not yet recruiting - Aortic Dissection Clinical Trials

A Real World Study on Fabulous® Thoracic Aortic Stent System for Stanford B Aortic Dissection

Start date: August 1, 2023
Phase:
Study type: Observational

A multicenter, retrospective study to evaluate the real-world efficacy of the Fabulous thoracic aortic stent system in the treatment of Stanford Type B aortic dissection.